• Je něco špatně v tomto záznamu ?

Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study

A. Chiricozzi, G. Coscarella, L. Puig, R. Vender, J. Yeung, JM. Carrascosa, S. Piaserico, P. Gisondi, C. Lynde, P. Ferreira, PM. Bastos, E. Dauden, L. Leite, J. Valerio, E. Del Alcázar-Viladomiu, E. Vilarrasa, M. Llamas-Velasco, M....

. 2024 ; 38 (11) : 2175-2185. [pub] 20240611

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003735

BACKGROUND: Scarce data related to the drug survival of biologic agents in psoriasis patients aged ≥65 years is available. OBJECTIVES: To evaluate the drug survival of interleukin (IL)-23 or the IL-17 inhibitors approved for the treatment of moderate-to-severe psoriasis in elderly patients (aged ≥65 years), compared with younger adult patients (aged <65 years), and to identify clinical predictors that can influence the drug survival. METHODS: This retrospective multicentric cohort study included adult patients with moderate-to-severe psoriasis, dissecting two-patient subcohorts based on age: elderly versus younger adults. Kaplan-Meier estimator and proportional hazard Cox regression models were used for drug survival analysis. RESULTS: We included 4178 patients and 4866 treatment courses; 934 were elderly (1072 treatment courses), and 3244 were younger patients (3794 treatment courses). Drug survival, considering all causes of interruption, was higher in patients aged <65 years than in elderly patients overall (log-rank p < 0.006). This difference was significant for treatment courses involving IL-23 inhibitors (p < 0.001) but not for those with IL-17 inhibitors (p = 0.2). According to both uni- and multi-variable models, elder age was associated with an increased risk of treatment discontinuation (univariable analysis: HR: 1.229, 95% CI 1.062-1.422; p < 0.006; multivariable analysis: HR: 1.199, 95% CI 1.010-1.422; p = 0.0377). Anti-IL-23 agents were associated with a reduced likelihood of treatment discontinuation after adjusting for other variables (HR: 0.520, 95% CI 0.368-0.735; p < 0.001). Being previously treated with IL-17 inhibitors increased the probability of discontinuation. CONCLUSIONS: Elderly patients with psoriasis have an increased risk of biologic treatment discontinuation compared with younger adult patients, particularly, if being treated with IL-23 inhibitors. However, in stratified analyses conducted in elderly patients, IL-23 inhibitors showed higher drug survival rates than IL-17 inhibitors.

2nd Department of Dermatology Venereology Aristotle University School of Medicine Thessaloniki Greece

Center for Health Technology and Services Research Porto Portugal

Clínica Médica Belém Lisbon Portugal

Department of Dermatology CAC ICBAS CHP Centro Académico Clínico ICBAS CHP Porto Portugal

Department of Dermatology Germans Trias i Pujol University Hospital Badalona Spain

Department of Dermatology Hospital de la Santa Creu i Sant Pau Barcelona Spain

Department of Dermatology Lausanne University Hospital CHUV and University of Lausanne Lausanne Switzerland

Department of Dermatology University of Pisa Pisa Italy

Department of Dermatovenereology 3rd Faculty of Medicine Charles University and Kralovske Vinohrady University Hospital Prague Czech Republic

Department of Medicine The Lynde Institute for Dermatology University of Toronto Toronto Ontario Canada

Department of Reconstructive and Aesthetic Plastic Surgery University of Milan Milan Italy

Dermatologia Dipartimento di Scienze Mediche e Chirurgiche Fondazione Policlinico Universitario A Gemelli IRCCS Rome Italy

Dermatologia Dipartimento Universitario di Medicina e Chirurgia Traslazionale Università Cattolica Del Sacro Cuore Rome Italy

Dermatology Center Hospital CUF Descobertas Lisbon Portugal

Dermatology Department Hospital Universitario de la Princesa Instituto de Investigación Sanitaria La Princesa Madrid Spain

Dermatology Unit Department of Medicine University of Padua Padua Italy

Division of Dermatology Department of Medicine Probity Medical Research University of Toronto Waterloo Ontario Canada

ITR Laboratory for Integrative and Translational Research in Population Health Porto Portugal

McMaster University Hamilton Ontario Canada

Section of Dermatology and Venereology Department of Medicine University of Verona Verona Italy

Section of Dermatology Department of Dermatological Science University of Florence Florence Italy

UMIB Unit for Multidisciplinary Research in Biomedicine Instituto de Ciências Biomédicas Abel Salazar University of Porto Porto Portugal

Unit of Dermatology University of Campania Luigi Vanvitelli Naples Italy

University Hospital of Venereal and Skin Diseases A Sygros Athens Greece

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003735
003      
CZ-PrNML
005      
20250206104645.0
007      
ta
008      
250121s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/jdv.20143 $2 doi
035    __
$a (PubMed)38860729
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Chiricozzi, Andrea $u Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica Del Sacro Cuore, Rome, Italy $u Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy $1 https://orcid.org/0000000267390387
245    10
$a Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study / $c A. Chiricozzi, G. Coscarella, L. Puig, R. Vender, J. Yeung, JM. Carrascosa, S. Piaserico, P. Gisondi, C. Lynde, P. Ferreira, PM. Bastos, E. Dauden, L. Leite, J. Valerio, E. Del Alcázar-Viladomiu, E. Vilarrasa, M. Llamas-Velasco, M. Alessandri-Bonetti, F. Messina, M. Bruni, EV. Di Brizzi, F. Ricceri, A. Nidegger, J. Hugo, A. Mufti, AI. Daponte, L. Teixeira, A. Balato, M. Romanelli, F. Prignano, S. Gkalpakiotis, C. Conrad, E. Lazaridou, N. Rompoti, AJ. Stratigos, M. Nogueira, K. Peris, T. Torres
520    9_
$a BACKGROUND: Scarce data related to the drug survival of biologic agents in psoriasis patients aged ≥65 years is available. OBJECTIVES: To evaluate the drug survival of interleukin (IL)-23 or the IL-17 inhibitors approved for the treatment of moderate-to-severe psoriasis in elderly patients (aged ≥65 years), compared with younger adult patients (aged <65 years), and to identify clinical predictors that can influence the drug survival. METHODS: This retrospective multicentric cohort study included adult patients with moderate-to-severe psoriasis, dissecting two-patient subcohorts based on age: elderly versus younger adults. Kaplan-Meier estimator and proportional hazard Cox regression models were used for drug survival analysis. RESULTS: We included 4178 patients and 4866 treatment courses; 934 were elderly (1072 treatment courses), and 3244 were younger patients (3794 treatment courses). Drug survival, considering all causes of interruption, was higher in patients aged <65 years than in elderly patients overall (log-rank p < 0.006). This difference was significant for treatment courses involving IL-23 inhibitors (p < 0.001) but not for those with IL-17 inhibitors (p = 0.2). According to both uni- and multi-variable models, elder age was associated with an increased risk of treatment discontinuation (univariable analysis: HR: 1.229, 95% CI 1.062-1.422; p < 0.006; multivariable analysis: HR: 1.199, 95% CI 1.010-1.422; p = 0.0377). Anti-IL-23 agents were associated with a reduced likelihood of treatment discontinuation after adjusting for other variables (HR: 0.520, 95% CI 0.368-0.735; p < 0.001). Being previously treated with IL-17 inhibitors increased the probability of discontinuation. CONCLUSIONS: Elderly patients with psoriasis have an increased risk of biologic treatment discontinuation compared with younger adult patients, particularly, if being treated with IL-23 inhibitors. However, in stratified analyses conducted in elderly patients, IL-23 inhibitors showed higher drug survival rates than IL-17 inhibitors.
650    _2
$a lidé $7 D006801
650    12
$a psoriáza $x farmakoterapie $7 D011565
650    _2
$a retrospektivní studie $7 D012189
650    12
$a interleukin-17 $x antagonisté a inhibitory $7 D020381
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    12
$a interleukin-23 $x antagonisté a inhibitory $7 D053759
650    _2
$a věkové faktory $7 D000367
650    _2
$a dospělí $7 D000328
650    _2
$a dermatologické látky $x terapeutické užití $7 D003879
650    _2
$a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Coscarella, Giulia $u Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica Del Sacro Cuore, Rome, Italy $u Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
700    1_
$a Puig, Luis $u Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain $1 https://orcid.org/0000000160830952
700    1_
$a Vender, Ron $u McMaster University, Hamilton, Ontario, Canada $1 https://orcid.org/0000000226242724
700    1_
$a Yeung, Jensen $u Division of Dermatology, Department of Medicine, Probity Medical Research, University of Toronto, Waterloo, Ontario, Canada
700    1_
$a Carrascosa, José-Manuel $u Department of Dermatology, Germans Trias i Pujol University Hospital (HUGTP), Autonomous University of Barcelona (UAB), Badalona, Spain $1 https://orcid.org/0000000342660771
700    1_
$a Piaserico, Stefano $u Dermatology Unit, Department of Medicine, University of Padua, Padua, Italy
700    1_
$a Gisondi, Paolo $u Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy $1 https://orcid.org/0000000217779001
700    1_
$a Lynde, Charles $u Department of Medicine, The Lynde Institute for Dermatology, University of Toronto, Toronto, Ontario, Canada
700    1_
$a Ferreira, Paulo $u Dermatology Center, Hospital CUF Descobertas, Lisbon, Portugal
700    1_
$a Bastos, Pedro Mendes $u Dermatology Center, Hospital CUF Descobertas, Lisbon, Portugal $1 https://orcid.org/000000022439920X
700    1_
$a Dauden, Esteban $u Dermatology Department, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria La Princesa (IIS-IP), Madrid, Spain $1 https://orcid.org/0000000206761260
700    1_
$a Leite, Luiz $u Clínica Médica Belém, Lisbon, Portugal
700    1_
$a Valerio, Joana $u Clínica Médica Belém, Lisbon, Portugal
700    1_
$a Del Alcázar-Viladomiu, Elena $u Department of Dermatology, Germans Trias i Pujol University Hospital (HUGTP), Autonomous University of Barcelona (UAB), Badalona, Spain $1 https://orcid.org/000000025935356X
700    1_
$a Vilarrasa, Eva $u Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
700    1_
$a Llamas-Velasco, Mar $u Dermatology Department, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria La Princesa (IIS-IP), Madrid, Spain $1 https://orcid.org/0000000211871341
700    1_
$a Alessandri-Bonetti, Mario $u Department of Reconstructive and Aesthetic Plastic Surgery, University of Milan, Milan, Italy
700    1_
$a Messina, Francesco $u Dermatology Unit, Department of Medicine, University of Padua, Padua, Italy $1 https://orcid.org/0000000279595881
700    1_
$a Bruni, Manfredo $u Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
700    1_
$a Di Brizzi, Eugenia Veronica $u Unit of Dermatology - University of Campania Luigi Vanvitelli, Naples, Italy $1 https://orcid.org/0000000202782443
700    1_
$a Ricceri, Federica $u Section of Dermatology, Department of Dermatological Science, University of Florence, Florence, Italy $1 https://orcid.org/0000000318834268
700    1_
$a Nidegger, Alessia $u Department of Dermatology, Lausanne University Hospital CHUV and University of Lausanne, Lausanne, Switzerland
700    1_
$a Hugo, Jan $u Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000243413812
700    1_
$a Mufti, Asfandyar $u Division of Dermatology, Department of Medicine, Probity Medical Research, University of Toronto, Waterloo, Ontario, Canada
700    1_
$a Daponte, Athina-Ioanna $u Second Department of Dermatology-Venereology, Aristotle University School of Medicine, Thessaloniki, Greece
700    1_
$a Teixeira, Laetitia $u Center for Health Technology and Services Research (CINTESIS), Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS.UP), Porto, Portugal
700    1_
$a Balato, Anna $u Unit of Dermatology - University of Campania Luigi Vanvitelli, Naples, Italy
700    1_
$a Romanelli, Marco $u Department of Dermatology, University of Pisa, Pisa, Italy
700    1_
$a Prignano, Francesca $u Section of Dermatology, Department of Dermatological Science, University of Florence, Florence, Italy $1 https://orcid.org/0000000259972045
700    1_
$a Gkalpakiotis, Spyridon $u Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000269565961 $7 xx0094696
700    1_
$a Conrad, Curdin $u Department of Dermatology, Lausanne University Hospital CHUV and University of Lausanne, Lausanne, Switzerland $1 https://orcid.org/0000000225473440
700    1_
$a Lazaridou, Elizabeth $u Second Department of Dermatology-Venereology, Aristotle University School of Medicine, Thessaloniki, Greece
700    1_
$a Rompoti, Natalia $u University Hospital of Venereal and Skin Diseases "A.Sygros", Athens, Greece $1 https://orcid.org/0000000293266726
700    1_
$a Stratigos, Alexander J $u University Hospital of Venereal and Skin Diseases "A.Sygros", Athens, Greece
700    1_
$a Nogueira, Miguel $u Department of Dermatology, CAC ICBAS-CHP - Centro Académico Clínico ICBAS - CHP, Porto, Portugal $1 https://orcid.org/000000017420408X
700    1_
$a Peris, Ketty $u Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica Del Sacro Cuore, Rome, Italy $u Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy $1 https://orcid.org/0000000319576600
700    1_
$a Torres, Tiago $u Department of Dermatology, CAC ICBAS-CHP - Centro Académico Clínico ICBAS - CHP, Porto, Portugal $u UMIB - Unit for Multidisciplinary Research in Biomedicine, Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal $u ITR - Laboratory for Integrative and Translational Research in Population Health, Porto, Portugal $1 https://orcid.org/0000000304040870
773    0_
$w MED00002983 $t Journal of the European Academy of Dermatology and Venereology $x 1468-3083 $g Roč. 38, č. 11 (2024), s. 2175-2185
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38860729 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104641 $b ABA008
999    __
$a ok $b bmc $g 2263483 $s 1239742
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 38 $c 11 $d 2175-2185 $e 20240611 $i 1468-3083 $m Journal of the European Academy of Dermatology and Venereology $n J Eur Acad Dermatol Venereol $x MED00002983
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace